Geneva Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Geneva Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-9,230	Closed	-$200K	–	747
2015 Q4	$200K	Buy	+9,230	New	+$180K	﹤0.01%	569
2015 Q3	–	Sell	-8,150	Closed	-$283K	–	702
2015 Q2	$283K	Hold	8,150	–	–	0.01%	537
2015 Q1	$212K	Sell	8,150 -3,000	-27%	-$55K	﹤0.01%	586
2014 Q4	$144K	Hold	11,150	–	–	﹤0.01%	616
2014 Q3	$137K	Hold	11,150	–	–	﹤0.01%	604
2014 Q2	$176K	Hold	11,150	–	–	﹤0.01%	606
2014 Q1	$169K	Buy	11,150 +1,150	+12%	+$13K	﹤0.01%	579
2013 Q4	$76K	Hold	10,000	–	–	﹤0.01%	501
2013 Q3	$34K	Buy	+10,000	New	+$26.4K	﹤0.01%	488

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Geneva Advisors's HZNP Position: Q1 2016 in Review

Geneva Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2016, closing a stake of 9,230 shares — an estimated $200K sold.

Geneva Advisors first reported a position in HZNP in Q3 2013 and held it in 9 quarters. The position peaked at $283K in Q2 2015. 196 funds tracked by Wall St. Rank hold HZNP as of Q1 2016.

Geneva Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2016 after selling out during the quarter.
Geneva Advisors sold 9,230 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2016, an estimated $200K.
Geneva Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 9 quarters.
Geneva Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $283K in Q2 2015.
196 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2016.

Based on Geneva Advisors's 13F filing for Q1 2016, filed 3 May 2016.